Inhibition of T cell activation and autoimmune diabetes using a B cell surface–linked CTLA-4 agonist
J. Clin. Invest. Brian T. Fife, et al. 116:2252 doi:10.1172/JCI27856 [Go to this article.]

Figure 6
NOD.scαCTLA-4 Tg⁺ mice are protected from spontaneous diabetes. Female NOD.scαCTLA-4 Tg⁺ mice and NOD littermate controls were monitored for the development of spontaneous autoimmune diabetes. Diabetes incidence is shown here for NOD (n = 17) (filled circles) and NOD.scαCTLA-4 Tg⁺ (n = 15) (open circles). NOD diabetes incidence reached 70% (12 of 17) by 30 weeks of age while diabetes incidence in NOD.scαCTLA-4 Tg⁺ mice was significantly reduced to 33% (5 of 15) by 30 weeks of age (P < 0.027).